An Open Label, Prospective, Clinical Study to Evaluate The Role Of Herbal Immunomodulators (Tab Immusante and Tab Guduchi) in Boosting the Immunity among healthcare workers assigned to COVID-19 wards

The Himalaya Drug Company0 个研究点目标入组 100 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Male or non-pregnant female subjects, aged 18-60 years old,
•2.High risk people like Health care workers (Doctors, Nurse, Laboratory technicians, Other hospital support staff), community health care workers assigned to COVID-19 wards.
•3. Female of child-bearing potential willing to follow reliable and strict contraceptive measures.
•4. Subjects judged to be reliable for compliance for taking medication and capable of recording the effects of the medication and motivated in receiving benefits from the treatment and willing to follow the regulations as per prevailing guidelines.
•5. Willing to give written informed consent to participate in the study.

•Current active/ Confirmed / relapsed COVID-19 positive cases
•2. Pregnant or lactating women.
•3. Recent history of significant lung disease like Asthma or Chronic Obstructive Lung Disease (COPD).
•4. Unable to take oral medication or suffering from ailments related to absorption.
•5. Suffering from Immunocompromising conditions or taking any immunosuppressing therapy.
•6. Subjects suffering from severe and uncontrolled metabolic/endocrinal/cardiac/renal/liver disease.
•7. The subject with known hypersensitivity to any of the test materials or related compounds.
•8. The subject who are unable or unwilling to comply fully with the study protocol.
•9. Physician makes a decision that trial involvement is not in subjectsâ?? best interest, or any condition that does not allow the protocol to be followed safely.

发起方